Cambridge Investment Research Advisors, Inc. Inmune Bio, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 23,075 shares of INMB stock, worth $182,061. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,075Holding current value
$182,061% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding INMB
# of Institutions
81Shares Held
7.07MCall Options Held
202KPut Options Held
42.9K-
Black Rock Inc. New York, NY813KShares$6.41 Million0.0% of portfolio
-
Praetorian Pr LLC Rincon, PR812KShares$6.41 Million1.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA738KShares$5.82 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$4.71 Million45.87% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL476KShares$3.75 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $142M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...